Get the Stockscreener App
0.2489
0.77%
0.0019
Pre-market:
.25
0.0011
+0.44%
Azitra Inc stock is traded at $0.2489, with a volume of 1.08M.
It is up +0.77% in the last 24 hours and down -40.02% over the past month.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.247
Open:
$0.2475
24h Volume:
1.08M
Relative Volume:
1.26
Market Cap:
$3.11M
Revenue:
$1.27M
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.0111
EPS:
-22.4496
Net Cash Flow:
$-10.46M
1W Performance:
-40.91%
1M Performance:
-40.02%
6M Performance:
-86.40%
1Y Performance:
-83.84%
1-Day Range:
$0.241
$0.2529
1-Week Range:
$0.24
$0.30
52-Week Range:
$0.0922
$12.00
Azitra Inc Stock (AZTR) Company Profile
Name
Azitra Inc
Sector
Industry
Phone
203 646 6446
Address
21 Business Park Drive, Branford
Compare AZTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZTR
Azitra Inc
|
0.2489 | 3.11M | 1.27M | -11.28M | -10.46M | -22.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Azitra Inc Stock (AZTR) Latest News
Branford biopharma firm Azitra prices $1.5M public stock offering - Hartford Business Journal
Azitra announces pricing of $1.5M public offering of common stock - MSN
SEC Form 424B5 filed by Azitra Inc - Quantisnow
Dow Jumps 600 Points; US Inflation Increases To 2.9% In December - Benzinga
Azitra sets price for $1.5 million stock offering - Investing.com
Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock - Nasdaq
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Why Vision Marine Technologies Shares Are Trading Higher By 68%; Here Are 20 Stocks Moving Premarket - Benzinga
Azitra launches public stock offering By Investing.com - Investing.com Australia
SEC Form 424B3 filed by Azitra Inc - Quantisnow
Azitra launches public stock offering - Investing.com
Azitra Announces Common Stock Public Offering with Maxim Group as Placement Agent - StockTitan
Azitra stock plunges to 52-week low of $0.38 amid steep decline By Investing.com - Investing.com South Africa
Azitra stock plunges to 52-week low of $0.38 amid steep decline - Investing.com Nigeria
Azitra (NYSEAMERICAN:AZTR) Trading 14% Higher – Should You Buy? - Defense World
Azitra, Inc. to Present at Biotech Showcase 2025 alongside the J.P. Morgan Annual Healthcare Conference - Marketscreener.com
Azitra, Inc. to Present at Biotech Showcase 2025 Alongside the J.P. Morgan Annual Healthcare Conference - StreetInsider.com
Azitra to Present Growth Strategy at Biotech Showcase 2025: Clinical Pipeline & Development Plans in Focus - StockTitan
Azitra stock plunges to 52-week low, hits $0.42 - Investing.com India
Azitra, Inc. Announces Q3 2024 Financial Results and Provides Bu - GuruFocus.com
AZTR: Planning 2nd Site for ATR-12 Trial - MSN
Azitra stock plunges to 52-week low at $0.46 amid steep decline - Investing.com Australia
500: Something went wrong - Investing.com Canada
Azitra (NYSEAMERICAN:AZTR) Shares Down 3.9% – Here’s Why - Defense World
Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates - PR Newswire
Azitra to Present at BIO-Europe 2024 - BioSpace
Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit - Marketscreener.com
Azitra Joins 2024 Maxim Healthcare Virtual Summit - FinancialNews.co.uk
Netherton Syndrome Treatment Industry is Expected to Reach $8 Billion by 2034 -Lifemax Laboratories, Azitra, Inc, Sixera – IndiaPolitics.com - IndiaPolitics.com
Azitra stock plunges to 52-week low, hits $0.49 By Investing.com - Investing.com South Africa
Azitra stock plunges to 52-week low, hits $0.49 - Investing.com
Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga
Azitra to present EGFR inhibitor toxicity treatment data By Investing.com - Investing.com Australia
Azitra to present EGFR inhibitor toxicity treatment data - Investing.com India
AZTRAzitra Inc Latest Stock News & Market Updates - StockTitan
Mexico's inflation undershoots forecasts ahead of rate decision - Investing.com
Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress - Business Wire
AZTR’s Market Fluctuations: Is Now the Right Time to Invest? - The InvestChronicle
FDA fast tracks Azitra's new dermatology treatment - Investing.com
Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors - StockTitan
Taking a Closer Look At Azitra Inc (AZTR) Following Its Recent Trade - Knox Daily
Azitra Inc Stock (AZTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Cap:
|
Volume (24h):